It is necessary to improve the capacity to diagnose Alzheimer’s disease before effective treatments can be developed and tested in clinical trials. The disease starts to affect brain cells decades before the appearance of symptoms of cognitive decline. The application and testing of treatments once cognitive dysfunction is evident is akin to focusing on developing drugs for late stage cancer. The most urgent need in the fight against Alzheimer’s disease is the development of cost-effective, reliable blood-based diagnosis of the accumulation of risk factors for the disease. NeoNeuro has spent the last three years developing a revolutionary approach to the development and application of a platform that will fill this need. We have developed innovations that enable us to select millions of small synthetic DNA sequences called aptamers that bind to molecular targets in blood that are diagnostic of various stages of the disease. We have used advances made in genome sequencing and computing power to characterize a subset of these aptamers, called Aptamarkers. These Aptamarkers can be rapidly and cost-effectively characterized on individual blood samples with simple technological platforms performed in existing blood testing laboratories globally. In our proof of principle experiments we demonstrated the efficacy of our approach with 42 cognitively normal subjects with 98% accuracy. The use of this tool to identify cognitively normal individuals with high levels of amyloid (a key risk factor for the onset of the disease) is useful for the pre-screening of potential enrollees in clinical trials. In this project we intend to validate this demonstration to a large set of individual samples with support from French and Australian research groups. We also intend to develop and demonstrate the efficacy of this approach for the prediction of the rate of disease progression.